PUBLISHER: DataM Intelligence | PRODUCT CODE: 1382519
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1382519
Allergic rhino conjunctivitis is a common chronic disorder in children, especially in developed countries. It does not cause nasal symptoms only (such as congestion and sneezing) but may also cause general complaints such as fatigue and cough. Although classic "hay fever" is easily recognised in children who have a runny nose, sneezing, and itchy eyes during the pollen season, the diagnosis of allergic rhino conjunctivitis is often missed in children with perennial nasal congestion.
Due to the high expense of healthcare, including doctor visits, prescriptions, and treatments, allergic rhino conjunctivitis can have a substantial financial impact. It can also result in lower efficiency at work and more absenteeism, which is harmful to both workers and employers. If allergic rhino conjunctivitis is not treated effectively, it might progress to consequences including sinusitis, an infection of the ears, or ear infections. These issues could lead to further discomfort and necessitate more medical attention.
The increasing prevalence of allergies, rising pollution levels, and growing awareness about the available treatment options are major factors driving market growth. For instance, according to WHO 2022, stated that, the combined effects of ambient air pollution and household air pollution are associated with 6.7 million premature deaths annually and ambient (outdoor) air pollution is estimated to have caused 4.2 million premature deaths worldwide in 2019.
Moreover, according to EPA, in 2022, about 65 million tons of pollution were emitted into the atmosphere in the United States. These emissions mostly contribute to the formation of ozone and particles, the deposition of acids, and visibility impairment. Thus rise of pollution levels accelerates the market growth.
New therapeutic approaches, drugs, and therapies are always being developed in the fields of allergy and immunology. A greater variety of efficient products for treating allergic rhino conjunctivitis have been produced as a result of medical science advancements. A increasing prevalence of allergies is a result of environmental changes such increased pollution and shifting climatic patterns.
While the allergic rhino conjunctivitis market continues to grow, there are several restraining factors that can impede its progress. For instance, while there are several drugs available to treat the symptoms of allergic rhino conjunctivitis, not everybody can benefit from them. Some people may only get temporary relief or unpleasant side effects, which makes them uncomfortable and less likely to follow through with prescribed therapies.
In addition, some antihistamines, especially those from earlier generations, might have adverse effects like sleepiness that lower users' quality of life. Although there are fewer adverse effects associated with newer drugs, safety concerns can still be a barrier, particularly for certain patient populations.
The global allergic rhino-conjunctivitis marketis segmented based on drug type, route of administration, age group, distribution channel and region.
Antihistamines allergic rhino conjunctivitis symptoms by inhibiting the action of histamine, a chemical released by the body when it feels it is under attack from an allergen. Antihistamines that target the histamine H1 receptor can help patients with allergic rhino conjunctivitis improve and maintain their quality of life. A classification based on their detailed characteristics is required for the more effective and safer second-generation drugs recommended by various guidelines. Oral antihistamines, in general, have been shown to relieve histamine-mediated symptoms associated with allergic rhino conjunctivitis effectively.
Second-generation antihistamines are useful for many patients with mild symptoms who require as-needed treatment because their onset of action is typically within 15 to 30 minutes. They are considered safe for children over the age of two. This segment is expected to dominate the market growth in the forecast period due to the increasing launches of antihistamines to treat allergic rhino conjunctivitis.
Revenue growth in North America is attributed to the rising number of patients with rhino conjunctivitis, government initiatives to promote awareness, and the rising demand for treatment are some of the key factors responsible for the market revenue growth in this region.
For instance, according to CDC, allergic conjunctivitis is the inflammation of the lining of the eye (conjunctiva) due to exposure to allergens like those in pollen. Allergic conjunctivitis is found in up to 30% of the general population and as many as 7 out of 10 of patients with allergic rhinitis. Symptoms from allergic conjunctivitis include red, watery, or itchy eyes. Thus, rise of disease in the region accelerates the region growth.
Due to the rising prevalence of allergic disorders, the dominance of major market players, and R&D for the creation of efficient and safer allergen-specific immunotherapy procedures, the market for allergy immunotherapies is expected to grow in Europe over the forecast period.
COVID-19, caused by the novel coronavirus SARS-CoV-2, primarily affects the respiratory system. While the virus primarily manifests with symptoms such as fever, cough, and difficulty breathing, there have been reports of various other symptoms and complications, including effects on the eyes and exacerbation of pre-existing conditions such as allergic rhino conjunctivitis.
The pandemic's focus on COVID-19 may make it more difficult to treat allergic rhino conjunctivitis. Due to concerns about exposure to COVID-19, people may postpone seeking medical assistance for allergy symptoms, which can result in mismanaged or improperly managed allergies. Individuals with allergic rhino conjunctivitis may be harmed by wearing masks, a typical COVID-19 prevention technique.
By Route of Administration
major global players in the market include: Sun Pharmaceutical Industries, Merck & Co., Inc, Novartis AG, Haleon Group, Lofarma S.p.A, ALK-Abello A/S, Stallergenes Greer, HAL Allergy B.V., Hikma Pharmaceuticals PLC, Bausch & Lomb and among others.
The global allergic rhino-conjunctivitis market report would provide approximately 69 tables, 58 figures and 187 Pages.
LIST NOT EXHAUSTIVE